The Case for Mach7 Technologies (M7T) M7T is in the business of...

The Case for Mach7 Technologies (M7T)
M7T is in the business of providing Enterprise Imaging Technology Solution for Global Health Enterprises with an application platform that is designed to solve the lack of interoperability of systems within hospitals (unlocks disparate archive silos, consolidates patient data) and simplifies sharing and access with the overall aim of improving patient care outcomes. This $30.5m mcap stock (at 23.5c) is little known compared to Promedicus (PME) which has its Visage imaging platform that makes imaging management and access more manageable, faster and flexible. PME is already a $800m mcap business. Essentially both businesses offer great value propositions for the management of imaging data for global health enterprises.
M7T already has an annual revenue base of $10.3m and an impressive year-on-year annual growth of 37% over the last 4 years. It has been winning a number of new contracts lately, the latest Sentara (US) deal of US$1.8m is not given a more deserved recognition in the current market price. M7T’s has its main presence in US where its most of its business is gained although it is now installed in 11 countries. It has an addressable market of US $3.8b and with its great value proposition should continue to underpin its revenue growth in the coming years.
I like M7T for its experienced management team ( its founder and management team previously from GE Healthcare), with a share base that is tightly held and now that it has divested from its problematic 3DM business, it is poised to scale IMO towards 40c which should give a mcap of $50m that is more appropriate or aligned to its achievements thus far. DYOR!